There are fewer than ten suits so far, the paper
cited one company insider as saying. It gave no details of the
A Bayer spokesman declined to comment on the newspaper's report
but said the drug's safety profile since its launch is
consistent with the results of clinical studies that involved
more than 75,000 patients.
Xarelto had sales of 949 million euros ($1.3 billion) last year
and Bayer Chief Executive Marijn Dekkers has said he expected
sales could reach around 3.5 billion euros annually.
Bayer peer Boehringer Ingelheim last month said it would pay
about $650 million to settle U.S. lawsuits that claimed the
company's blockbuster blood thinner, Pradaxa, had caused severe
and fatal bleeding in patients. [ID:nL3N0OE3RI]
Boehringer said it expected to resolve about 4,000 claims with
the settlement. The claimants had accused the company of not
issuing sufficient warnings of the risks associated with
(Reporting by Frank Siebelt and Jonathan Gould, editing by
[© 2014 Thomson Reuters. All rights
Copyright 2014 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.